Last updated: 11/30/2018 00:10:22
Open, randomised, multicenter, Phase II clinical trial to assess the immunogenicity and reactogenicity of GlaxoSmithKline (GSK) Biologicals' dTpa-IPV vaccine compared to GSK Biologicals' dTpa (Boostrix™) and Aventis Pasteur Merck Sharp Dohme’s (MSD) IPV (Imovax Polio®) vaccines administered separately, and to assess immunogenicity and reactogenicity of GSK Biologicals' DTPa-IPV vaccine (Infanrix-IPV™), when administered to healthy adolescents aged 10-14 years.
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Open, randomised, multicenter, Phase II clinical trial to assess the immunogenicity and reactogenicity of GlaxoSmithKline (GSK) Biologicals' dTpa-IPV vaccine compared to GSK Biologicals' dTpa (Boostrix™) and Aventis Pasteur Merck Sharp Dohme’s (MSD) IPV (Imovax Polio®) vaccines administered separately, and to assess immunogenicity and reactogenicity of GSK Biologicals' DTPa-IPV vaccine (Infanrix-IPV™), when administered to healthy adolescents aged 10-14 years.
Trial description: Open, randomised, multicenter, Phase II clinical trial to assess the immunogenicity and reactogenicity of GlaxoSmithKline (GSK) Biologicals' dTpa-IPV vaccine compared to GSK Biologicals' dTpa (Boostrix™) and Aventis Pasteur Merck Sharp Dohme’s (MSD) IPV (Imovax Polio®) vaccines administered separately, and to assess immunogenicity and reactogenicity of GSK Biologicals' DTPa-IPV vaccine (Infanrix-IPV™), when administered to healthy adolescents aged 10-14 years.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Vergara R et al. (2005) Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age. Eur J Pediatr. 164(6): 377-382.
Medical condition
Diphtheria, Tetanus, acellular pertussis
Product
Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine
Collaborators
Not applicable
Study date(s)
March 2002 to June 2002
Type
Not applicable
Phase
2
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2002-20-06
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website